

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicants: Andrew VAILLANT et al.  
Serial number: 10/661,088  
Filing date: September 12, 2003  
For: ANTIVIRAL OLIGONUCLEOTIDES TARGETING HBV  
Art Unit: 1648  
Examiner: HURT, Sharon L.  
Agent: Cawthorn, Christian (514) 847-4256

-----  
**TERMINAL DISCLAIMER UNDER 37 C.F.R. §1.321(c)**

Assistant Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450  
U.S.A.

Sir:

The Petitioner, REPLICOR INC., hereby disclaims, except as provided below, the terminal part of the statutory term of any patent granted on the above-captioned application, which would extend beyond the expiration date of the full statutory term defined in 35 U.S.C. §§154 to 156 and 173, of copending U.S. Application No. 10/661,088, and agrees that any patent granted on the above-captioned patent application shall be enforceable only for and during such period that the legal title to such patent shall be the same as the legal title to said copending U.S. Application No. 10/661,088, this agreement is to run with said U.S. Patent Application No. 10/661,403, and any patent granted on the above-captioned patent application, and is to be binding upon the grantee, its successors or assigns.

In making the above disclaimer, REPLICOR INC. does not disclaim the terminal part of any patent granted on the above-captioned application that would extend to the expiration date of the full statutory term as defined in 35 U.S.C. §§154 to 156 and 173 of any patent granted on said copending U.S. Patent Application No. 10/661,088 in the event that it later expires for failure to pay a maintenance fee, is held unenforceable, is found invalid by a

Assistant Commissioner for Patents

Court of competent jurisdiction, is statutorily disclaimed in whole or terminally disclaimed under 37 C.F.R. §1.321, has all claims cancelled by reexamination certificate, is reissued, or is in any manner terminated prior to the expiration of its full statutory term. In addition, any patent granted on this application or any patent subject to reexamination proceedings shall be enforceable only for and during such period that said patent is commonly owned with the application or patent which formed the basis for the judicially created double patenting.

Since Applicants claimed small entity status, the Commissioner is hereby authorized to charge fees of \$65.00, under 37 C.F.R. § 1.20(d), which may be required by this paper. The Commissioner is hereby authorized to charge and to credit any overpayment to Deposit Account No. 19-5113.

Respectfully,



Christian Cawthorn, Reg. No. 47,352  
Agent for Applicants  
Tel: (514) 847-4256  
Fax: (514) 288-8389

February 9, 2007

Date

OGILVY RENAULT LLP  
1981 McGill College, Suite 1600  
Montreal, Quebec H3A 2Y3  
CANADA